Roche says CELESTIMO phase III met primary endpoint
Roche said its phase III CELESTIMO study met its primary endpoint, with Lunsumio plus lenalidomide improving progression-free survival versus rituximab plus lenalidomide in relapsed/refractory follicular lymphoma. Overall survival data were immature and no new safety signals were reported.
Roche said its phase III CELESTIMO study met the primary endpoint, with Lunsumio plus lenalidomide significantly improving progression-free survival versus rituximab plus lenalidomide in relapsed/refractory follicular lymphoma. Overall survival data were immature, and Roche said no new safety signals were seen.